Free Trial

Michael Freeman Analyst Performance

Analyst at Raymond James Financial

Michael Freeman is a stock analyst at Raymond James Financial in the medical sector, covering 4 publicly traded companies. Over the past year, Michael Freeman has issued 4 stock ratings, including strong buy and buy recommendations. While full access to Michael Freeman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Freeman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
100.00% 4 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy50.0%2 ratings
Buy50.0%2 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Michael Freeman at Raymond James Financial, the majority (50.0%) have been Strong Buy recommendations, followed by 50.0% Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Michael Freeman, an analyst at Raymond James Financial, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Michael Freeman of Raymond James Financial specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
100.0%

Michael Freeman's Ratings History at Raymond James Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
6/11/2025Initiated Coverage$33.62$65.00Strong-Buy
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
6/11/2025Initiated Coverage$7.28$14.00Outperform
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
6/11/2025Initiated Coverage$25.04$76.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
6/11/2025Initiated Coverage$52.22$89.00Strong-Buy